search
Back to results

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Primary Purpose

GERD With Erosive Esophagitis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
AZD0865
Sponsored by
AstraZeneca
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for GERD With Erosive Esophagitis focused on measuring GERD with erosive esophagitis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone. Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1. Erosive esophagitis according to LA classification Grade A, B, C or D, at the visit 1 endoscopy. Have provided Informed consent. Exclusion Criteria: Subjects with current or historical evidence of the following conditions are excluded from the study: Esophageal stricture. Primary esophageal motility disorder(s), i.e. diffuse esophageal spasm, achalasia. Systemic Sclerosis (scleroderma). Irritable Bowel Syndrome (IBS), i.e. upper abdominal discomfort or pain that in the opinion of the Investigator is likely to be due to IBS or fulfilling two or more of the criteria: relieved by defecation, associated with change in frequency of stools, associated with change in form (appearance) of stools. Inflammatory bowel disease. Zollinger-Ellison syndrome. Gastric ulcer, duodenal ulcer or duodenal erosions within the last 3 months Subjects with i) history of significant or ii) current significant or unstable: Cardiovascular diseases or cardiac chest pain. Cerebrovascular diseases, such as cerebral ischemia, infarction, haemorrhage, or embolus. Diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable. Pulmonary, renal, pancreatic or liver diseases or any other serious disease as judged by the investigator to interfere with the evaluation of the current study. Malignant disease (except for minor superficial skin disease). Generalised bleeding disorders.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Siteq
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Siteq
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Outcomes

Primary Outcome Measures

Healing of erosive esophagitis at 4 weeks.

Secondary Outcome Measures

Healing of erosive esophagitis at 2 and 8 weeks.
The Quality of Life in Reflux and Dyspepsia (QOLRAD).
Patient-reported symptoms.
Investigator-reported symptoms.
Population pharmacokinetics (PK). Area under the concentration-time curve (AUC) and the oral clearance calculated by dose/AUC (CL/F).
pH monitoring.
Histology.
Safety (Adverse events, Laboratory variables, BP, pulse, ECG and physical examination).

Full Information

First Posted
September 13, 2005
Last Updated
January 3, 2013
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00206245
Brief Title
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
Official Title
A Randomised, Double-blind, Multicentre Dose-finding Phase IIb Study for up to 8 Weeks' Treatment With AZD0865 25, 50, 75 mg and Esomeprazole 40 mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
AstraZeneca

4. Oversight

5. Study Description

Brief Summary
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate the safety and tolerability of AZD0865.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
GERD With Erosive Esophagitis
Keywords
GERD with erosive esophagitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1400 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
AZD0865
Primary Outcome Measure Information:
Title
Healing of erosive esophagitis at 4 weeks.
Secondary Outcome Measure Information:
Title
Healing of erosive esophagitis at 2 and 8 weeks.
Title
The Quality of Life in Reflux and Dyspepsia (QOLRAD).
Title
Patient-reported symptoms.
Title
Investigator-reported symptoms.
Title
Population pharmacokinetics (PK). Area under the concentration-time curve (AUC) and the oral clearance calculated by dose/AUC (CL/F).
Title
pH monitoring.
Title
Histology.
Title
Safety (Adverse events, Laboratory variables, BP, pulse, ECG and physical examination).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone. Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1. Erosive esophagitis according to LA classification Grade A, B, C or D, at the visit 1 endoscopy. Have provided Informed consent. Exclusion Criteria: Subjects with current or historical evidence of the following conditions are excluded from the study: Esophageal stricture. Primary esophageal motility disorder(s), i.e. diffuse esophageal spasm, achalasia. Systemic Sclerosis (scleroderma). Irritable Bowel Syndrome (IBS), i.e. upper abdominal discomfort or pain that in the opinion of the Investigator is likely to be due to IBS or fulfilling two or more of the criteria: relieved by defecation, associated with change in frequency of stools, associated with change in form (appearance) of stools. Inflammatory bowel disease. Zollinger-Ellison syndrome. Gastric ulcer, duodenal ulcer or duodenal erosions within the last 3 months Subjects with i) history of significant or ii) current significant or unstable: Cardiovascular diseases or cardiac chest pain. Cerebrovascular diseases, such as cerebral ischemia, infarction, haemorrhage, or embolus. Diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable. Pulmonary, renal, pancreatic or liver diseases or any other serious disease as judged by the investigator to interfere with the evaluation of the current study. Malignant disease (except for minor superficial skin disease). Generalised bleeding disorders.
Facility Information:
Facility Name
Research Site
City
Alabaster
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Huntsville
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
North Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Research Site
City
Anaheim
State/Province
California
Country
United States
Facility Name
Research Site
City
Cypress
State/Province
California
Country
United States
Facility Name
Research Site
City
Garden Grove
State/Province
California
Country
United States
Facility Name
Research Site
City
Lancaster
State/Province
California
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
Research Site
City
Mission Hills
State/Province
California
Country
United States
Facility Name
Research Site
City
Orange
State/Province
California
Country
United States
Facility Name
Research Site
City
Rancho Cucamonga
State/Province
California
Country
United States
Facility Name
Research Site
City
San Diego
State/Province
California
Country
United States
Facility Name
Research Site
City
Torrance
State/Province
California
Country
United States
Facility Name
Research Site
City
Wheat Ridge
State/Province
Colorado
Country
United States
Facility Name
Research Site
City
Manchester
State/Province
Connecticut
Country
United States
Facility Name
Research Site
City
Davie
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Gainesville
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Jupiter
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Ocoee
State/Province
Florida
Country
United States
Facility Name
Research Site
City
W Palm Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Zephyr Hills
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Austell
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Conyers
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Moline
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Rockford
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Clive
State/Province
Iowa
Country
United States
Facility Name
Research Site
City
Overland Park
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Metairie
State/Province
Louisiana
Country
United States
Facility Name
Research Site
City
Shreveport
State/Province
Louisiana
Country
United States
Facility Name
Research Site
City
Annapolis
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Hollywood
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Laurel
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Towson
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Picayune
State/Province
Mississippi
Country
United States
Facility Name
Research Site
City
Jefferson City
State/Province
Missouri
Country
United States
Facility Name
Research Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
Research Site
City
Butte
State/Province
Montana
Country
United States
Facility Name
Research Site
City
Willingboro
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Elkin
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Fayetteville
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Greensboro
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Greenville
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
High Point
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Raleigh
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Canton
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Guthrie
State/Province
Oklahoma
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
Research Site
City
Duncansville
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Anderson
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Georgetown
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Mt Pleasant
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Simpsonville
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Bristol
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Jackson
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Knoxville
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Ogden
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Christiansburg
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Norfolk
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
Research Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
Research Site
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
Research Site
City
Abbotsford
State/Province
British Columbia
Country
Canada
Facility Name
Research Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
Research Site
City
St. John's
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
Research Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
Research Site
City
Guelph
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
North York
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Thornhill
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Research Site
City
Levis
State/Province
Quebec
Country
Canada
Facility Name
Research Site
City
Longueuil
State/Province
Quebec
Country
Canada
Facility Name
Research Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Research Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
Research Site
City
Quebec
Country
Canada
Facility Name
Research Site
City
Aalborg
Country
Denmark
Facility Name
Research Site
City
Birkerød
Country
Denmark
Facility Name
Research Site
City
Esbjerg
Country
Denmark
Facility Name
Research Site
City
Herning
Country
Denmark
Facility Name
Research Site
City
Holbæk
Country
Denmark
Facility Name
Research Site
City
Hvidovre
Country
Denmark
Facility Name
Research Site
City
Kolding
Country
Denmark
Facility Name
Research Site
City
København K
Country
Denmark
Facility Name
Research Site
City
København NV
Country
Denmark
Facility Name
Research Site
City
Odense
Country
Denmark
Facility Name
Research Site
City
Randers
Country
Denmark
Facility Name
Research Site
City
Vejle
Country
Denmark
Facility Name
Research Site
City
Viborg
Country
Denmark
Facility Name
Research Site
City
Århus C
Country
Denmark
Facility Name
Research Site
City
Espoo
Country
Finland
Facility Name
Research Site
City
Helsinki
Country
Finland
Facility Name
Research Site
City
Lahti
Country
Finland
Facility Name
Research Site
City
Mikkeli
Country
Finland
Facility Name
Research Site
City
Pori
Country
Finland
Facility Name
Research Site
City
Tampere
Country
Finland
Facility Name
Research Site
City
Turku
Country
Finland
Facility Name
Research Site
City
Vantaa
Country
Finland
Facility Name
Research Site
City
Ales
Country
France
Facility Name
Research Site
City
Angers
Country
France
Facility Name
Research Site
City
Beausoleil
Country
France
Facility Name
Research Site
City
Bordeaux
Country
France
Facility Name
Research Site
City
Caen
Country
France
Facility Name
Research Site
City
Cannes La Bocca
Country
France
Facility Name
Research Site
City
Choisy Le Roi
Country
France
Facility Name
Research Site
City
Dreux
Country
France
Facility Name
Research Site
City
Hazebrouck
Country
France
Facility Name
Research Site
City
Issoire
Country
France
Facility Name
Research Site
City
Marseille
Country
France
Facility Name
Research Site
City
Narbonne
Country
France
Facility Name
Research Site
City
Paris
Country
France
Facility Name
Research Site
City
Saint Quentin
Country
France
Facility Name
Research Site
City
Talence
Country
France
Facility Name
Research Site
City
Vitry Sur Seine
Country
France
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
Celle
Country
Germany
Facility Name
Research Site
City
Dresden
Country
Germany
Facility Name
Research Site
City
Görlitz
Country
Germany
Facility Name
Research Site
City
Köln
Country
Germany
Facility Name
Research Site
City
Leipzig
Country
Germany
Facility Name
Research Site
City
Ludwigshafen
Country
Germany
Facility Name
Research Site
City
Magdeburg
Country
Germany
Facility Name
Research Site
City
Mainz
Country
Germany
Facility Name
Research Site
City
München
Country
Germany
Facility Name
Research Site
City
Oelde
Country
Germany
Facility Name
Research Site
City
Potsdam
Country
Germany
Facility Name
Research Site
City
Ribnitz-Damgarten
Country
Germany
Facility Name
Research Site
City
Wolmirstedt
Country
Germany
Facility Name
Research Site
City
Bologna
Country
Italy
Facility Name
Research Site
City
Brescia
Country
Italy
Facility Name
Research Site
City
Genova
Country
Italy
Facility Name
Research Site
City
Mestre
Country
Italy
Facility Name
Research Site
City
Milano
Country
Italy
Facility Name
Research Site
City
Napoli
Country
Italy
Facility Name
Research Site
City
Palermo
Country
Italy
Facility Name
Research Site
City
Parma
Country
Italy
Facility Name
Research Site
City
Pisa
Country
Italy
Facility Name
Research Site
City
Roma
Country
Italy
Facility Name
Research Site
City
Bergen
Country
Norway
Facility Name
Research Site
City
Bodø
Country
Norway
Facility Name
Research Siteq
City
Drammen
Country
Norway
Facility Name
Research Site
City
Gjøvik
Country
Norway
Facility Name
Research Site
City
Levanger
Country
Norway
Facility Name
Research Site
City
Nesttun
Country
Norway
Facility Name
Research Site
City
Oslo
Country
Norway
Facility Name
Research Site
City
Stavanger
Country
Norway
Facility Name
Research Site
City
Tromsø
Country
Norway
Facility Name
Research Site
City
Trondheim
Country
Norway
Facility Name
Research Site
City
Karlskrona
Country
Sweden
Facility Name
Research Site
City
Kristianstad
Country
Sweden
Facility Name
Research Site
City
Kungälv
Country
Sweden
Facility Name
Research Site
City
Malmö
Country
Sweden
Facility Name
Research Site
City
Mora
Country
Sweden
Facility Name
Research Site
City
Nyköping
Country
Sweden
Facility Name
Research Site
City
Skövde
Country
Sweden
Facility Name
Research Site
City
Stockholm
Country
Sweden
Facility Name
Research Site
City
Sundsvall
Country
Sweden
Facility Name
Research Site
City
Säffle
Country
Sweden
Facility Name
Research Site
City
Täby
Country
Sweden
Facility Name
Research Site
City
Varberg
Country
Sweden
Facility Name
Research Site
City
Värnamo
Country
Sweden
Facility Name
Research Siteq
City
Östersund
Country
Sweden
Facility Name
Research Site
City
Ashford
Country
United Kingdom
Facility Name
Research Site
City
Atherstone
Country
United Kingdom
Facility Name
Research Site
City
Cambridge
Country
United Kingdom
Facility Name
Research Site
City
Cheltenham
Country
United Kingdom
Facility Name
Research Site
City
Coventry
Country
United Kingdom
Facility Name
Research Site
City
Derby
Country
United Kingdom
Facility Name
Research Site
City
Dundee
Country
United Kingdom
Facility Name
Research Site
City
Dunfermline
Country
United Kingdom
Facility Name
Research Site
City
Epsom
Country
United Kingdom
Facility Name
Research Site
City
Glasgow
Country
United Kingdom
Facility Name
Research Site
City
Hamilton
Country
United Kingdom
Facility Name
Research Site
City
Kent
Country
United Kingdom
Facility Name
Research Site
City
Lancaster
Country
United Kingdom
Facility Name
Research Site
City
Manchester
Country
United Kingdom
Facility Name
Research Site
City
Slough
Country
United Kingdom
Facility Name
Research Site
City
Somerset
Country
United Kingdom
Facility Name
Research Site
City
Stafford
Country
United Kingdom
Facility Name
Research Site
City
Stockport
Country
United Kingdom
Facility Name
Research Site
City
Telford
Country
United Kingdom
Facility Name
Research Site
City
Torquay
Country
United Kingdom
Facility Name
Research Site
City
West Bromwich
Country
United Kingdom
Facility Name
Research Site
City
West Yorks
Country
United Kingdom
Facility Name
Research Site
City
Woking
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
25039978
Citation
Kahrilas PJ, Persson T, Denison H, Wernersson B, Hughes N, Howden CW. Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. Aliment Pharmacol Ther. 2014 Sep;40(6):648-56. doi: 10.1111/apt.12877. Epub 2014 Jul 15.
Results Reference
derived
PubMed Identifier
23831734
Citation
Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. Gut. 2014 May;63(5):720-6. doi: 10.1136/gutjnl-2013-304883. Epub 2013 Jul 5.
Results Reference
derived

Learn more about this trial

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

We'll reach out to this number within 24 hrs